Back to results
US 11,229,697 B2Granted
Vaccines against genital herpes simplex infections
AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorKonstantin G. Kousoulas
Life of this patent
Estimating the term…
Abstract
The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.
Claims9
An recombinant herpes simplex virus (HSV) genome comprising:
- (a) a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type glycoprotein K (gK);
- (b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein;
- (c) a deletion of a non-essential HSV gene;
- and
- (d) a gene encoding a heterologous antigen;
- wherein a virus comprising the recombinant HSV genome is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
3 more elements
An immunogenic composition or virus comprising a recombinant HSV genome comprising:
- (a) a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK;
- (b) a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein;
- (c) a deletion of a non-essential HSV gene;
- and
- (d) a gene encoding a heterologous antigen;
- wherein a virus comprising the recombinant HSV genome is capable of replication in a host cell and incapable of entry into axonal compartments of neurons.
3 more elements
A method for producing a vaccine or immunogenic composition, the method comprising:
- (a) transfecting a host cell with a recombinant HSV genome comprising
- i. a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK,
- ii. a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein;
- iii. a deletion of a non-essential HSV gene, and
- iv. a gene encoding a heterologous antigen,
- wherein a virus comprising the recombinant HSV genome is capable of replication in a host cell and incapable of entry into axonal compartments of neurons;
- and
- (b) incubating the transfected host cell under conditions favorable for the formation of a recombinant HSV virus comprising the recombinant HSV genome;
- (c) purifying the recombinant HSV virus comprising the recombinant HSV genome;
- and optionally
- (d) combining the purified recombinant HSV virus with at least one pharmaceutically acceptable component.
8 more elements
A method for producing a recombinant HSV, the method comprising:
- (a) transfecting a host cell with a recombinant HSV genome comprising
- i. a modified UL53 gene comprising a deletion corresponding to the region of the UL53 gene that encodes amino acids 31-68 of wild-type gK,
- ii. a modified UL20 gene comprising a deletion corresponding to the region of the UL20 gene that encodes amino acids 4-22 of wild-type UL20 protein,
- iii. a deletion of a non-essential HSV gene, and
- iv. a gene encoding a heterologous antigen,
- wherein a virus comprising the recombinant HSV genome is capable of replication in a host cell and incapable of entry into axonal compartments of neurons;
- and
- (b) incubating the transfected host cell under conditions favorable for the formation of a recombinant HSV virus comprising the recombinant HSV genome, whereby a recombinant HSV is produced.
5 more elements
Dependencies are inferred from the claim text.